Sai Life Sciences Limited
Pharmaceuticals
Annual Returns


Cumulative Returns and Drawdowns


Ownership

Margined

AI Summary
asof: 2026-09-16
Sai Life Sciences — Q1FY27 and Recent Announcements
1. Headwinds and Challenges
- The company operates in a single segment — Contract Research,
Development and Manufacturing Services (CRDMO) — so performance is tied
to demand from innovator pharmaceutical and biotech clients rather than
diversified businesses.
- The Labour Codes notified by the Government of India on 21 November
2025 changed the definition of wages, increasing gratuity liability
(past service cost) and compensated absences liability by Rs. 82.93
million for the quarter and nine months ended 31 December 2025. This was
treated as an exceptional, non-recurring item. A reassessment in the
quarter ended 31 March 2026, based on a revised remuneration structure,
produced a credit of Rs. 2.92 million, leaving a net expense of Rs.
80.01 million for FY26. The company has stated that further
clarification from the Government on other aspects of the Labour Codes
will be evaluated and any differential impact accounted for in
subsequent periods.
- Forward-looking statements in the company’s own disclosures flag
risks and uncertainties including: general economic and business
conditions in India; ability to successfully implement strategy;
research and development efforts; growth and expansion plans; obtaining
regulatory approvals; provisioning policies; technological changes;
investment and business income; cash flow projections; exposure to
market risks; changes in laws and regulations applicable to
pharmaceuticals; increasing competition; and changes in political
conditions in India.
- The analyst/institutional investor meeting schedule is subject to
change due to exigencies on the part of participants or the
company.
2. Tailwinds and Growth Prospects
- Q1FY27 revenue from operations was ₹554 crore, up 12% year-on-year,
with growth across both CRO and CDMO businesses. CRO grew 24%
year-on-year.
- The CMC pipeline continues to strengthen, with 33 active commercial
molecules and 14 late-phase molecules.
- Management describes an evolution in what large pharmaceutical
companies seek from outsourcing partners — scientifically led partners
who take greater ownership of integrated discovery and development
programs rather than executing individual pieces of work. Sai Life
believes its technology base, scientific talent and culture are key
reasons large pharmaceutical companies are bringing significant work to
it through strategic engagements, which management expects to create a
healthy and sustained pipeline over multiple years.
- Encouraging traction is reported in the FTE-led engagement
model.
- Growth prospects cited include expansion in CRO and CDMO businesses,
expansion in new-age modalities such as peptides, ADCs and oligos, and
digitization and automation initiatives.
- The company has expanded relationships with global pharmaceutical
partners, added new commercial molecules, strengthened strategic
collaborations, successfully undergone major regulatory inspections, and
completed its IPO in December 2024.
- Consolidated revenue increased from ₹870 crore in FY2022 to ₹2,242
crore in FY2026; EBITDA rose from ₹131 crore to ₹661 crore; PAT rose
from ₹6 crore to ₹349 crore, reflecting improvements in scale,
profitability and operational excellence.
- The company reports over 300 active global clients, including 19 of
the top 25 global pharma companies, 3,800+ total employees, world-class
R&D and manufacturing facilities, and a 100% successful track record
of regulatory inspections.
- During Q1FY27 the company operationalized a new 100,000 sq. ft.
R&D facility at Genome Valley, Hyderabad, and achieved an EcoVadis
Platinum Rating for sustainability, joining the top 1% of companies
assessed worldwide.
3. Key Risks
- Risks and uncertainties explicitly noted in the company’s
forward-looking statements: ability to successfully implement strategy,
growth and expansion plans, obtain regulatory approvals, provisioning
policies, technological changes, investment and business income, cash
flow projections, and exposure to market risks.
- Broader factors cited: general economic and business conditions in
India, research and development efforts, changes in laws and regulations
applicable to pharmaceuticals, increasing competition, and changes in
political conditions in India.
- The company cautions that forward-looking statements are not
guarantees of future performance and that undue reliance should not be
placed on them; it assumes no obligation to update forward-looking
statements except as required by applicable securities laws.
- Potential further financial impact from the Labour Codes remains
open, pending any additional Government clarification.
Broker Timeline
1 broker calls · 2026-10-21 to 2026-10-21
CNBC-TV18: ratings, targets and commentary
No recorded CNBC-TV18 statements for this ticker.
Management comments
No recorded management comments with an explicit designation and affiliation for this ticker.
Copyright © 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.
🐞